HUGE News and Press, FSD Pharma Inc. From 10/05/20

MyoKardia (MYOK) +59% as Bristol to acquire the company for $225/Share.Kosmos Energy (KOS) +50% as company closed a Gulf of Mexico facility with Beal Bank USA and Trafigura Trading LLC.Enlivex Therapeutics (ENLV) +49%.Corvus Pharmaceuticals (CRVS) +38% on co-foun...

Oxbridge Re Holdings (OXBR) +96%.Perceptron (PRCP) +67% on entering agreement to be acquired by Atlas Copco.Westwater Resources (WWR) +58%.Genfit SA (GNFT) +43% on NASH test deal with LabCorp.Lithium Americas (LAC) +29%.NexTier Oilfield Solutions (NEX) +23%.OpGen (OPGN)&#x...

FSD Pharma (HUGE) says FDA has authorized the initiation of a Phase 2 study for the use of FSD201 (ultramicronized palmitoylethanolamide, or ultramicronized PEA) to treat COVID-19, the disease caused by the SARS-CoV-2 virus (the "FSD201 COVID-19 Trial").The company is expected to start dosing...

- FDA has authorized randomized, controlled, double-blind, multicenter study on 352 patients TORONTO, ON / ACCESSWIRE / September 28, 2020 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE.CN) (" FSD Pharma " or the " Company ") today announced that the U.S. Food and Drug Administration (" FD...

AstraZeneca reports positive data for Phase III Farxiga trial AstraZeneca ( AZN ) reported that Farxiga has shown robust decline in the risk of kidney failure, cardiovascular or renal death in patients suffering from chronic kidney disease. The data from the Phase III DAPA-CKD trial show...

Zosano Pharma (NASDAQ: ZSAN )   -14%  on planned equity offering. More news on: Zosano Pharma Corporation, VivoPower International PLC, FSD Pharma Inc., Stocks on the move, , Read more ...

Aimmune Therapeutics (NASDAQ: AIMT ) +171%  on being acquired by Nestle. More news on: Aimmune Therapeutics, Inc., Akcea Therapeutics, Inc., Genworth Financial, Inc., , , Read more ...

FSD Pharma (NASDAQ: HUGE ) has submitted to the FDA an Investigational New Drug Application (IND) for the use of FSD201 (ultramicronized palmitoylethanolamide, or ultramicronized PEA) to treat COVID-19 (the “FSD201 COVID-19 Trial”). More news on: FSD Pharma Inc., Healthca...

- The study is expected to be conducted at 25-30 hospitals in North America - FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE.CN) (“ FSD Pharma ” or the “ Company ”) today announced that it has submitted to the U.S. Food and Drug Administration (“ ...

- The study is expected to be conducted at 25-30 hospitals in North America - TORONTO, ON / ACCESSWIRE / August 31, 2020 / FSD Pharma Inc. (CSE:HUGE)(NASDAQ:HUGE)(FRA:0K9A) (" FSD Pharma " or the " Company ") today announced that it has submitted to the U.S. Food and Drug Administr...